Biorce Healthtech Startup Secures €5M to Accelerate Drug Development With AI

This comes just seven months after its €3.5 million seed round in November 2024, led by YZR Capital and Mustard Seed Maze.

Clinical trials are vital for bringing new treatments to patients—but many face major delays. About 70% are delayed at the startup phase, and nearly 60% need costly changes later, costing up to $450K each. These issues often stem from poor trial design, miscommunication, and logistics errors.

Read Also - Germany’s Cariqa Secures €4M To Make EV Charging Easier And More Transparent

Biorce is tackling this head-on. Its AI-powered platform simplifies clinical trial operations—from designing protocols to picking the right trial sites and recruiting patients. The goal is to reduce delays, improve trial success rates, and get new therapies to patients faster. With Biorce’s technology, pharmaceutical companies can save millions and accelerate innovation in healthcare.

Pedro Coelho CEO of Biorce, shared: We’re tackling the root causes of delay and inefficiency in clinical trials: issues that cost time, money, and ultimately lives. Our solution cuts through complexity, shortens timelines, and improves outcomes for patients. When my father was diagnosed with cancer, we were lucky to find a clinical trial that extended his life by ten months, but that kind of access is far from the norm. Our goal is to make clinical trials faster and cheaper so that we can get those opportunities to all patients and not just those lucky enough to join a trial.

At the heart of Biorce’s solution is its AI-native platform, Jarvis, designed to help clinical teams make smarter decisions early in the trial process. Jarvis gives personalized recommendations and predicts which trial sites are most likely to succeed—reducing delays, avoiding costly errors, and speeding up the path to launch new therapies.

Biorce’s platform is already delivering results. It’s being used by top pharmaceutical companies, biotechs, and CROs to improve trial planning and protocol design. The system works across different medical fields like oncology and neurology, helping teams accelerate timelines through more informed and efficient choices.

Since joining Norrsken Barcelona, Biorce has seen strong demand and has doubled its team size since raising its first round in November 2024.

Tove Larsson, General Partner at Norrsken VC, explained: Biorce is exactly the kind of pioneering company we’re here to back. They’re combining deep sector expertise with cutting-edge AI to solve what truly matters. Their platform has the potential to radically reduce both the time and cost of bringing new treatments to market, unlocking huge value for pharma and, more importantly, faster access to life-saving therapies for patients.

Recently, Norrsken VC, along with Norrsken Launcher and Norrsken Accelerator, announced a €300 million commitment to support European startups that are using AI to solve major global challenges.

Markus Feuerecker, Founding Partner at YZR Capital, shared that they are proud to have supported Biorce early in 2024.

From day one, we had a strong conviction in the team and the market. The early traction has been outstanding, and it’s been exciting to watch their momentum build. We’re thrilled to welcome Norrsken VC on board and to join forces in supporting Biorce on its mission to transform clinical trials.

Sofia Queiroz, Investment Principal at Mustard Seed Maze, added: Biorce’s journey since we backed Pedro and the team has been truly impressive — from strong product development and real-world outcomes to tangible commercial traction. This rapid growth demonstrates that the company is addressing a genuine market need and has the right team in place to capture the opportunity. We’re excited to continue supporting Biorce and to welcome Norrsken VC as a fellow impact investor on this journey.

The clinical trial market is expected to grow from $84 billion in 2024 to $150 billion by 2034, with rising R&D spending from pharmaceutical companies. AI tools like Biorce’s Jarvis could unlock $13–25 billion in value by cutting trial amendments by 30–50% and improving protocols 25% faster.

Biorce currently operates in Spain, the UK, and the Nordics. With the new funding, the company plans to expand its U.S. sales team, speed up product development, and scale operations.

About Biorce

Founded in 2024, Biorce helps improve clinical trial design with Jarvis, the first AI protocol assistant built for research. Trained on 500,000+ studies, Jarvis offers smart suggestions, feasibility checks, and regulatory insights. Biorce supports pharma, biotech, and CROs to reduce delays, cut waste, and launch better trials faster.